THE INVESTOR

메뉴열기

[EQUITIES] ‘Hanmi Pharma to gain from strong pipeline’

PUBLISHED : January 10, 2018 - 13:52

UPDATED : January 10, 2018 - 13:52

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Hanmi Pharmaceutical has turned to black in the fourth quarter last year and has a series of R&D projects in store this year, said Mirae Asset Daewoo on Jan. 10, maintaining a “buy” recommendation and 710,000 won (US$662.93) target price. 



Its revenue hiked 32.4 percent on-year to 227.8 billion won and operating profit turned to black at 18.8 billion won, although the figures were lower than expected, said analyst Kim Tae-heui.

It is the most advanced developer of novel medicines among Korean pharma companies, and has a strong pipeline that raises expectations for this year, noted the analyst, adding that concerns over its key platform technology Labscovery have cleared and additional technology exports could be expected.

By Hwang You-mee (glamazon@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.